For the quarter ending 2026-03-31, HOWL had $35,009K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 38,909 | -16,370 | -36,071 |
| Stock-based compensation expense | -4,103 | 1,233 | 3,799 |
| Depreciation expense | -836 | 402 | 832 |
| Non-cash interest expense | -966 | 551 | 1,010 |
| Non-cash lease expense | -361 | 198 | 381 |
| Loss on extinguishment of debt | - | 0 | 0 |
| Change in fair value of derivative liability | 459 | 25 | 190 |
| Prepaid expenses and other assets | -278 | -457 | 574 |
| Deferred revenue | - | 0 | 0 |
| Other receivables | - | 0 | 0 |
| Accounts payable, accrued expenses and other liabilities | 5,476 | -1,205 | -2,348 |
| Operating lease liability | 733 | -397 | -951 |
| Net cash used in operating activities | 38,671 | -15,156 | -34,112 |
| Purchases of property and equipment | - | 0 | 0 |
| Net cash used in investing activities | - | 0 | 0 |
| Proceeds from at the market offering of common stock, net of issuance costs | - | 3,274 | 347 |
| Proceeds from drawdown of term loans | - | 0 | 0 |
| Payment of debt issuance costs | - | 0 | 0 |
| Repayment of term loan | - | 0 | 0 |
| Proceeds from issuances under employee stock purchase plan | - | 0 | 41 |
| Proceeds from stock option exercises | - | 0 | 0 |
| Net cash provided by financing activities | - | 3,274 | 388 |
| Net decrease in cash, cash equivalents and restricted cash and cash equivalents | 35,009 | -11,882 | -33,724 |
| Cash, cash equivalents and restricted cash and cash equivalentsbeginning of period | -8,658 | 112,215 | - |
| Cash, cash equivalents and restricted cash and cash equivalentsend of period | -19,255 | 66,609 | - |
Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc. (HOWL)